Key Highlights Werewolf Therapeutics (HOWL) entered into an all-stock merger agreement with Ambros Therapeutics, with the unified entity set to trade under ticker “AMBX” on Nasdaq The merged
Shares of Werewolf Therapeutics (HOWL) experienced a dramatic 127% spike during Friday’s premarket session, reaching $0.9780, following dual announcements that reshaped the company’s trajectory.
Werewolf Therapeutics, Inc., HOWL
The primary announcement centered on an all-stock merger arrangement with Ambros Therapeutics. Following completion, the unified organization will adopt the Ambros Therapeutics brand and anticipates trading on Nasdaq with the ticker symbol “AMBX.”
Concurrent with the merger revelation, both companies disclosed they had finalized $150 million in private placement capital. The oversubscribed funding round saw co-leadership from RA Capital Management and Janus Henderson Investors, while Aberdeen Investments, Adage Capital Partners, and Balyasny Asset Management joined as additional participants.
$HOWL – Werewolf Therapeutics and Ambros Therapeutics
Announce Merger Agreement
— John Zidar aka/ Stock Wizard (@JohnZidar) August 21, 2026
According to the companies, the capital infusion should sustain operations until topline data emerges from the pivotal CRPS-RISE Phase 3 study in 2028. Management projects the merged entity’s financial runway will stretch into early 2029.
Central to this strategic combination is neridronate, an investigational therapy under assessment for warm CRPS-1 patients. Approximately 65,000 Americans receive a new CRPS-1 diagnosis annually, yet no FDA-sanctioned treatments exist for this debilitating condition.
The FDA has already granted neridronate Breakthrough Therapy, Fast Track, and Orphan Drug status. The compound holds regulatory approval in Italy for CRPS and related indications, with roughly 600,000 patients having received treatment there.
According to Ambros Therapeutics, the company’s intellectual property estate, paired with Orphan Drug protections, may provide U.S. market exclusivity extending to 2045.
The transaction assigns Ambros an implied valuation of $500 million, while Werewolf carries a pre-financing valuation of $47.5 million. Upon deal closure, ownership distribution is anticipated as follows: Ambros shareholders at approximately 71.7%, Werewolf shareholders at roughly 6.8%, and private placement investors at about 21.5%.
Subject to shareholder consent, the merger should finalize during the first quarter of 2027.
Through a separate arrangement, Werewolf signed an asset purchase agreement with EMD Serono Research & Development Institute, an affiliate of Merck KGaA (MKKGY), executed August 14 and revealed in an August 20 regulatory filing.
The terms call for EMD Serono to provide $28 million upfront, followed by $5 million once technology transfer concludes. The transaction encompasses Werewolf’s preclinical INDUCER platform alongside select INDUKINE assets.
Werewolf maintained rights essential for advancing its WTX-124 and WTX-330 clinical initiatives. Additionally, EMD Serono provided Werewolf with exclusive licensing rights to specific transferred patents supporting those development programs.
During Friday’s premarket session, HOWL exchanged hands at $0.9780, representing a 127% gain.
The post Werewolf Therapeutics (HOWL) Stock Soars 127% on Ambros Merger and $150M Financing Deal appeared first on Blockonomi.
